Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (FAP): Updated Safety and Efficacy
Dec 8, 2025 at 8:00 AM EST
Recursion presented a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in Familial Adenomatous Polyposis (FAP) at a company webinar on December 8, 2025. View the replay on YouTube: https://youtube.com/live/nCj4jE1honA
Presenters:
- Najat Khan, Ph.D., Chief R&D and Chief Commercial Officer and incoming CEO and President, Recursion
- David Mauro, M.D., Ph.D., Chief Medical Officer, Recursion
- Beth Bruckheimer, Ph.D., Vice President of Clinical Development, Recursion
- Jessica Stout, D.O., Assistant Clinical Professor, University of Utah School of Medicine
- Alfred Cohen, M.D., Former CMO, Cancer Prevention Pharmaceuticals; Prior Chief, Colorectal Service, Memorial Sloan Kettering Cancer Center